Drug Trial Radar · NCT07715305
A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers
Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Aug 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study compare and evaluate the bioequivalence between the administration of AD-116A and the administration of AD-1161 in healthy adult male volunteers
Conditions
- Benign Prostatic Hyperplasia
Interventions
AD-116ADrug
Oral Capsule
AD-1161Drug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration-time curve during dosing interval (AUCt)Time frame: pre-dose (0hour) to 72hours
- Maximum concentration of drug in plasma (Cmax)Time frame: pre-dose (0hour) to 72hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
H PLUS YANGJI HOSPITAL, Seoul
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.